© Datamonitor the home of Business Intelligence intuitive deliveryexpert analysisquality data © Datamonitor

PharmaVitae: MAP Pharmaceuticals HC Slidepack 01/12 quality dataexpert analysisintuitive delivery the home of Business Intelligence

MAP Pharmaceuticals prescription pharmaceutical performance, sales ($m) and growth rate (%), 2010–16

MAP Pharmaceuticals financial performance ($m), 2004–16

SWOT analysis of MAP Pharmaceuticals Positive data with Levadex. Levadex is expected to present a new choice for triptan non-responders. Collaboration with Allergan. Strengths Few early-stage products. Levadex is not the first non-injectable DHE product for migraine. The Tempo inhaler is cumbersome. MAP is not a profitable company. Weaknesses Relative lack of competition could lead to healthy uptake of Levadex. Additional treatment settings and indications. Partnerships and pipeline opportunities. Opportunities Early-stage candidates await partners. Patients usually prefer oral formulations. Reimbursement tiering is a concern. The FDA has had issues with inhaled products. Threats

© Datamonitor the home of Business Intelligence intuitive deliveryexpert analysisquality data © Datamonitor